Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 20/20 | 0.70 |
| ▸ | MMP13 | P45452 | 18/20 | 0.70 |
| ▸ | MMP9 | P14780 | 9/20 | 0.70 |
| ▸ | MMP2 | P08253 | 9/20 | 0.70 |
| ▸ | MMP3 | P08254 | 8/20 | 0.70 |
| ▸ | MMP7 | P09237 | 6/20 | 0.70 |
| ▸ | MMP8 | P22894 | 5/20 | 0.70 |
| ▸ | ADAM17 | P78536 | 14/20 | 0.68 |
| ▸ | MMP14 | P50281 | 2/20 | 0.65 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.64 |
| ▸ | ADAM9 | Q13443 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7057156 | 1.00 | MMP1 (0.70) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL7054578 | 0.92 | MMP1 (0.69) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL7054574 | 0.92 | MMP1 (0.69) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL7057249 | 0.91 | MMP1 (0.77) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL7057253 | 0.91 | MMP1 (0.77) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL7051193 | 0.90 | MMP1 (0.70) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL7051190 | 0.90 | MMP1 (0.70) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL7055124 | 0.89 | MMP1 (0.73) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL7055128 | 0.89 | MMP1 (0.73) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL7054577 | 0.88 | MMP1 (0.63) | MMP1MMP13MMP9MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073682-A1 | Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors | VOSS MATTHEW E (US) | 2003-04-17 | — | — | US | claimed |
| US-6365587-B1 | FOR THERAPY OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTITIS, GINGIVITIS, CORNEAL ULCERATION, MULTIPLE SCLEROSIS, NEURODEGENERATIVE DISEASES, PSORIASIS, AUTOIMMUNE DISEASE, CROHN'S DISEASE, INFLAMMATORY BOWEL DISEASE, OR HIV | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-02 | — | — | US | claimed |
| US-20030073682-A1 | Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors | VOSS MATTHEW E (US) | 2003-04-17 | — | — | US | disclosed |
| US-6365587-B1 | FOR THERAPY OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTITIS, GINGIVITIS, CORNEAL ULCERATION, MULTIPLE SCLEROSIS, NEURODEGENERATIVE DISEASES, PSORIASIS, AUTOIMMUNE DISEASE, CROHN'S DISEASE, INFLAMMATORY BOWEL DISEASE, OR HIV | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073682-A1 | Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors | MMP3, MMP10, MMP2 | MMP1 8/4885MMP13 13/4885MMP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.